European Studies Help Plan A Path Forward For Value Added Medicines
Six value added medicines case studies across six European countries are featured in the latest IQVIA report for Medicines for Europe. Each of them, according to the association’s sector chair Arun Narayan, helps point to a way forward for value added medicines in Europe.
You may also be interested in...
Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.